AU628913B2 - Pyrazolopyridine compound and processes for preparation thereof - Google Patents

Pyrazolopyridine compound and processes for preparation thereof Download PDF

Info

Publication number
AU628913B2
AU628913B2 AU48696/90A AU4869690A AU628913B2 AU 628913 B2 AU628913 B2 AU 628913B2 AU 48696/90 A AU48696/90 A AU 48696/90A AU 4869690 A AU4869690 A AU 4869690A AU 628913 B2 AU628913 B2 AU 628913B2
Authority
AU
Australia
Prior art keywords
compound
salt
formula
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU48696/90A
Other languages
English (en)
Other versions
AU4869690A (en
Inventor
Atsushi Akahane
Hirohito Katayama
Takafumi Mitsunaga
Youichi Shiokawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of AU4869690A publication Critical patent/AU4869690A/en
Application granted granted Critical
Publication of AU628913B2 publication Critical patent/AU628913B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU48696/90A 1989-01-23 1990-01-23 Pyrazolopyridine compound and processes for preparation thereof Ceased AU628913B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898901423A GB8901423D0 (en) 1989-01-23 1989-01-23 Pyrazolopyridine compound and processes for preparation thereof
GB8901423 1989-01-23

Publications (2)

Publication Number Publication Date
AU4869690A AU4869690A (en) 1990-07-26
AU628913B2 true AU628913B2 (en) 1992-09-24

Family

ID=10650453

Family Applications (1)

Application Number Title Priority Date Filing Date
AU48696/90A Ceased AU628913B2 (en) 1989-01-23 1990-01-23 Pyrazolopyridine compound and processes for preparation thereof

Country Status (23)

Country Link
US (1) US4985444A (https=)
EP (1) EP0379979B1 (https=)
JP (2) JPH0794454B2 (https=)
KR (1) KR0159502B1 (https=)
CN (1) CN1031570C (https=)
AT (1) ATE150462T1 (https=)
AU (1) AU628913B2 (https=)
CA (1) CA2008263C (https=)
DE (1) DE69030206T2 (https=)
DK (1) DK0379979T3 (https=)
ES (1) ES2098229T3 (https=)
FI (1) FI96205C (https=)
GB (1) GB8901423D0 (https=)
GR (1) GR3023219T3 (https=)
HU (2) HUT53368A (https=)
IE (1) IE900161L (https=)
IL (1) IL93050A (https=)
NO (1) NO176356C (https=)
PH (1) PH30968A (https=)
PT (1) PT92935B (https=)
RU (1) RU2007403C1 (https=)
UA (1) UA43821C2 (https=)
ZA (1) ZA90200B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU651353B2 (en) * 1990-07-18 1994-07-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and processes for preparation thereof

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155114A (en) * 1989-01-23 1992-10-13 Fujisawa Pharmaceutical Company, Ltd. Method of treatment using pyrazolopyridine compound
US5338743A (en) * 1988-06-06 1994-08-16 Fujisawa Pharmaceutical Co., Ltd. New use of the adenosine antagonist
GB9107513D0 (en) * 1991-04-10 1991-05-29 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
DE69315836T2 (de) * 1992-06-10 1998-04-09 Fujisawa Pharmaceutical Co Pyrazolpyridine für die behandlung der anämie
CA2148502A1 (en) * 1993-09-06 1995-03-16 Fumio Suzuki Antidepressants
CN1046724C (zh) * 1993-12-29 1999-11-24 藤泽药品工业株式会社 吡唑并吡啶化合物、含有它们的药物组合物、及其制法与用途
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
RU2172742C2 (ru) * 1995-12-28 2001-08-27 Пфайзер Инк. Стимуляторы секреции гормона роста
WO1997040047A1 (en) * 1996-04-25 1997-10-30 Fujisawa Pharmaceutical Co., Ltd. Preventives and remedies for ischemic intestinal lesion and ileus
AUPO111096A0 (en) * 1996-07-18 1996-08-08 Fujisawa Pharmaceutical Co., Ltd. New compound
ATE229527T1 (de) * 1996-10-04 2002-12-15 Kyorin Seiyaku Kk Pyrazolopyridylpyrazinon-derivate und ein verfahren zu ihrer herstellung
WO1998041237A1 (en) * 1997-03-18 1998-09-24 Fujisawa Pharmaceutical Co., Ltd. Preventives and remedies for hyperphosphatemia
DK1032575T3 (da) 1997-09-05 2003-10-20 Glaxo Group Ltd 2,3-diaryl-pyrazol(1,5-b)pyridazinderivater, deres fremstilling og anvendelse som cyclooxygenase 2 (COX-2) inhibitor
ES2273487T3 (es) * 1998-06-01 2007-05-01 Astellas Pharma Inc. Antagonistas a1 de adenosina contra la esterilidad masculina.
WO1999067239A1 (en) * 1998-06-22 1999-12-29 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compounds and medicinal uses thereof
AUPP672198A0 (en) * 1998-10-23 1998-11-19 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
US7223772B1 (en) 1998-11-03 2007-05-29 Smithkline Beecham Corporation Pyrazolopyridine derivatives as selective cox-2 inhibitors
US6541634B2 (en) 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
ATE261444T1 (de) 1999-02-27 2004-03-15 Glaxo Group Ltd Pyrazolopyridine
US20040152659A1 (en) * 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
AUPQ441499A0 (en) * 1999-12-02 2000-01-06 Fujisawa Pharmaceutical Co., Ltd. Novel compound
GB9930358D0 (en) 1999-12-22 2000-02-09 Glaxo Group Ltd Process for the preparation of chemical compounds
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AUPQ969800A0 (en) * 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
ATE301653T1 (de) * 2000-12-15 2005-08-15 Glaxo Group Ltd Pyrazolopyridine
JP2004515550A (ja) * 2000-12-15 2004-05-27 グラクソ グループ リミテッド 治療用化合物
ES2316546T3 (es) * 2001-02-20 2009-04-16 Astrazeneca Ab 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3.
WO2002072581A2 (en) * 2001-03-08 2002-09-19 Smithkline Beecham Corporation Pyrazolopyriadine derivatives
WO2002078701A1 (en) * 2001-03-30 2002-10-10 Smithkline Beecham Corporation Use of pyrazolopyridines as therapeutic compounds
WO2002078700A1 (en) * 2001-03-30 2002-10-10 Smithkline Beecham Corporation Pyralopyridines, process for their preparation and use as therapteutic compounds
ES2266487T3 (es) * 2001-04-10 2007-03-01 Smithkline Beecham Corporation Compuestos de pirazolopirina antivirales.
HUP0401292A3 (en) * 2001-04-27 2011-01-28 Eisai R & D Man Co Pyrazolo[1,5-a]pyridines, pharmaceutical compositions containing the same and process for preparation thereof
US6756498B2 (en) 2001-04-27 2004-06-29 Smithkline Beecham Corporation Process for the preparation of chemical compounds
ATE296826T1 (de) * 2001-04-27 2005-06-15 Smithkline Beecham Corp Pyrazolo(1,5)pyridinderivate
AUPR548601A0 (en) * 2001-06-06 2001-06-28 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyrazinecompound and pharmaceutical use thereof
ATE337316T1 (de) * 2001-06-21 2006-09-15 Smithkline Beecham Corp Imidazo 1,2-aöpyridin-derivate zur prophylaxe und behandlung von herpes-infektionen
US20040214834A1 (en) * 2001-09-07 2004-10-28 Kristjan Gudmunsson Pyrazolo-pyridines for the treatment of herpes infections
EP1432712B1 (en) * 2001-10-05 2006-05-17 SmithKline Beecham Corporation Imidazo-pyridine derivatives for use in the treatment of herpes viral infection
AUPR916301A0 (en) * 2001-11-29 2001-12-20 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
JP2005516916A (ja) * 2001-12-11 2005-06-09 スミスクライン ビーチャム コーポレーション 抗ヘルペス薬としてのピラゾロ−ピリジン誘導体
US20040021778A1 (en) * 2002-08-05 2004-02-05 Oldani Jerome L. Security system with remote access and control
GB0218876D0 (en) * 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
JP2006504728A (ja) * 2002-10-03 2006-02-09 スミスクライン ビーチャム コーポレーション ピラソロピリジン誘導体系治療用化合物
RU2008152776A (ru) * 2006-06-06 2010-07-20 Эвиджен Инк. (Us) СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
KR100809368B1 (ko) * 2006-08-09 2008-03-05 한국과학기술원 성대파를 이용한 음색 변환 시스템
RU2394034C2 (ru) * 2007-04-26 2010-07-10 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН ПРОИЗВОДНЫЕ 4,6-ДИМЕТИЛ-2,3-ДИГИДРО-1Н-ПИРАЗОЛО[4,3-c]ПИРИДИН-3-ОНОВ И ЭФИРЫ 2,6-ДИМЕТИЛ-4-ФЕНИЛ-ГИДРАЗИНОНИКОТИНОВЫХ КИСЛОТ В КАЧЕСТВЕ ПРОМЕЖУТОЧНЫХ ПРОДУКТОВ ДЛЯ ИХ СИНТЕЗА, ОБЛАДАЮЩИЕ АНТИДЕПРЕССАНТНОЙ И АНКСИОЛИТИЧЕСКОЙ АКТИВНОСТЬЮ
EP2266990B1 (en) 2008-04-15 2012-09-26 Eisai R&D Management Co., Ltd. 3-PHENYLPYRAZOLO[5,1-b]THIAZOLE COMPOUND
WO2010144416A1 (en) * 2009-06-08 2010-12-16 Gaeta Federico C A SUBSTITUTED PYRAZOLO [1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY
AR078521A1 (es) * 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
EP2487177A1 (en) * 2009-10-08 2012-08-15 Eisai R&D Management Co., Ltd. Pyrazoloxazole compound
WO2011074658A1 (ja) 2009-12-18 2011-06-23 田辺三菱製薬株式会社 新規抗血小板薬
SI2841437T1 (sl) 2012-04-26 2017-09-29 Bristol-Myers Squibb Company Derivati imidazotiadiazola in imidazopirazina kot proteazno aktivirani receptor 4 (PAR4) inhibitorji za zdravljenje agregacije trombocitov
EP2855489B1 (en) 2012-04-26 2017-01-04 Bristol-Myers Squibb Company Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
SG11201406759YA (en) 2012-04-26 2014-11-27 Bristol Myers Squibb Co Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
US9572528B1 (en) 2012-08-06 2017-02-21 Los Angeles Biomedical Research Insitute at Harbor-UCLA Medical Center Monitor for SIDS research and prevention
EP3004100B1 (en) * 2013-05-28 2018-06-27 RaQualia Pharma Inc. Polymorph forms
US9617279B1 (en) 2014-06-24 2017-04-11 Bristol-Myers Squibb Company Imidazooxadiazole compounds
US9598419B1 (en) 2014-06-24 2017-03-21 Universite De Montreal Imidazotriazine and imidazodiazine compounds
RU2695649C2 (ru) * 2014-08-05 2019-07-25 Раквалиа Фарма Инк. Производные серина в качестве агонистов грелиновых рецепторов
IL286481B2 (en) * 2019-03-20 2025-12-01 Goldfinch Bio Inc Pyridazinones and methods of use thereof
WO2022071777A1 (ko) * 2020-09-29 2022-04-07 연세대학교 산학협력단 호흡기 질환의 예방 또는 치료용 조성물 및 예방 또는 치료 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587931B2 (en) * 1987-04-01 1989-08-31 Boehringer Mannheim Gmbh Chromogenic compounds, processes for the preparation thereof and the use thereof as enzyme substrates
AU594170B2 (en) * 1986-07-08 1990-03-01 Synthelabo Nitrofuran derivatives, their preparation and compositions containing them
AU605518B2 (en) * 1986-11-26 1991-01-17 Japanese Foundation For Cancer Research Promoting agents of the activity of some antitumor agents against various kinds of tumor cells including multiple drug resistant tumor cells and their synthetic methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5154583A (en) * 1974-11-01 1976-05-13 Kyorin Seiyaku Kk Shinkipirazoro * 1 55a * pirijinjudotaino seizoho
NZ204589A (en) * 1982-06-16 1985-12-13 May & Baker Ltd 3-(n,n-dimethylcarbamoyl)-pyrazolo(1,5-a)pyridine and pharmaceutical compositions
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594170B2 (en) * 1986-07-08 1990-03-01 Synthelabo Nitrofuran derivatives, their preparation and compositions containing them
AU605518B2 (en) * 1986-11-26 1991-01-17 Japanese Foundation For Cancer Research Promoting agents of the activity of some antitumor agents against various kinds of tumor cells including multiple drug resistant tumor cells and their synthetic methods
AU587931B2 (en) * 1987-04-01 1989-08-31 Boehringer Mannheim Gmbh Chromogenic compounds, processes for the preparation thereof and the use thereof as enzyme substrates

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU651353B2 (en) * 1990-07-18 1994-07-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and processes for preparation thereof

Also Published As

Publication number Publication date
PT92935A (pt) 1990-07-31
GB8901423D0 (en) 1989-03-15
NO176356C (no) 1995-03-22
HU211684A9 (en) 1995-12-28
ATE150462T1 (de) 1997-04-15
JPH0881465A (ja) 1996-03-26
ZA90200B (en) 1990-10-31
NO900306D0 (no) 1990-01-22
EP0379979A1 (en) 1990-08-01
FI900307A0 (fi) 1990-01-19
DE69030206D1 (de) 1997-04-24
RU2007403C1 (ru) 1994-02-15
IL93050A (en) 1995-05-26
US4985444A (en) 1991-01-15
NO900306L (no) 1990-07-24
PT92935B (pt) 1995-12-29
EP0379979B1 (en) 1997-03-19
IL93050A0 (en) 1990-11-05
CN1044656A (zh) 1990-08-15
JPH0794454B2 (ja) 1995-10-11
ES2098229T3 (es) 1997-05-01
KR900011773A (ko) 1990-08-01
CA2008263A1 (en) 1990-07-23
UA43821C2 (uk) 2002-01-15
DE69030206T2 (de) 1997-07-10
GR3023219T3 (en) 1997-07-30
NO176356B (no) 1994-12-12
CN1031570C (zh) 1996-04-17
CA2008263C (en) 2000-03-14
KR0159502B1 (ko) 1998-12-01
HU900228D0 (en) 1990-03-28
PH30968A (en) 1997-12-23
DK0379979T3 (https=) 1997-04-07
HUT53368A (en) 1990-10-28
FI96205B (fi) 1996-02-15
JPH02243689A (ja) 1990-09-27
AU4869690A (en) 1990-07-26
FI96205C (fi) 1996-05-27
IE900161L (en) 1990-07-23

Similar Documents

Publication Publication Date Title
AU628913B2 (en) Pyrazolopyridine compound and processes for preparation thereof
US5155114A (en) Method of treatment using pyrazolopyridine compound
AU651353B2 (en) Pyrazolopyridine compound and processes for preparation thereof
EP0370381B1 (en) 2(1H)-quinolinone compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
AU694157B2 (en) Pyrazolopyridine adenosine antagonists
SK199592A3 (en) Heterocycylic compounds, their manufacture and use
CA1309095C (en) Aminoimidazoquinoline derivatives
EP0636626A1 (en) Pyrazolopyrimidine Derivatives
JPH04346978A (ja) ベンズイミダゾール類及びこれらの化合物を含有する薬剤組成物
US5354759A (en) Angiotenin II antagonizing heterocyclic compounds
MXPA06014699A (es) Derivados de pirazolo-piridina.
WO2004082616A2 (en) Tetrahydropyranyl cyclopentyl heterocylic amide modulators of chemokine receptor activity
JP2004512323A (ja) Ｃｃｒ５ケモカイン受容体活性のピロリジンモジュレーター
AU597190B2 (en) Therapeutic agents
US20090298872A1 (en) Compounds and compositions as modulators of steroidal receptors and calcium channel activities
KR20250023365A (ko) 알파 4 베타 7 인테그린 조정제 및 그의 용도
JPH10513172A (ja) ５−ｈｔ▲下１ｄ▼受容体アゴニストとしての置換１，４−ピペラジン−ヘテロアリール誘導体
EP0553682A1 (en) Imidazo 4,5-b pyridine derivatives as Angiotensin II antagonists
KR20060092219A (ko) 유도성 ｎｏ-합성효소 억제제로서의 아미노피리딘-유도체
EP1915373B1 (en) Heterobicyclic compounds useful as p38 kinase inhibiting agents
US5348960A (en) Imidazo[4,5-b]quinolinyl oxy alkyl tetrazolyl piperidine derivatives
JPS59141580A (ja) インド−ル誘導体
CA2631794A1 (en) P38 kinase inhibiting agents

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired